Locations:
Search
Refinements introduced to Cleveland Clinic-developed approach to a rare defect
But it is no substitute for clinical judgment
Cleveland Clinic-led study supports investigation of similar immunomodulatory therapies
Intermediate-term results of REGROUP trial extend earlier findings
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
And two case vignettes where some of them come into play
How the technology helped maintain transplant volume during a pandemic year
Large Cleveland Clinic series underscores challenges of decision-making for this rare defect
The procedure is safe, but prepare for AF recurrence rates approaching 50%
JACC State-of-the-Art Review features care algorithm and more
Investigators urge caution until more data accrue
Advertisement
Advertisement